

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 April 2024 (25.04.2024)



(10) International Publication Number
WO 2024/086579 A2

(51) International Patent Classification:
A61K 31/711 (2006.01) *A61P 31/04* (2006.01)

(21) International Application Number:
PCT/US2023/077091

(22) International Filing Date:
17 October 2023 (17.10.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/416,840 17 October 2022 (17.10.2022) US
63/495,243 10 April 2023 (10.04.2023) US
63/538,981 18 September 2023 (18.09.2023) US

(71) Applicant: **ACURX PHARMACEUTICALS, INC.**
[US/US]; 259 Liberty Ave., Staten island, New York 10305
(US).

(72) Inventors: **GARY, Kevin**; 311 W. 24TH Street, Hous-
ton, Texas 77018 (US). **BASSÈRES, Eugénie**; 606 Harold
Street, Apt. #4, Houston, Texas 77006 (US).

(74) Agent: **LENTZ, Shannon**; Crowell & Moring LLP, 1001
Pennsylvania Ave NW, Washington, District of Columbia
20004 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: COMPOUNDS AND METHODS FOR IMPROVING HEALTH




Figure 1A

(57) Abstract: The technical field relates to methods for promoting gut microbiome health using low G+C Directed (LDN) analogs. More particularly, the technical field relates to methods of using LDN analogs as inhibitors of DNA Polymerase III (DNA pol III) enzyme to selectively reduce physiologically harmful Gram-positive bacteria with a genome having low amounts of Guanine and Cytosine (rather the genomes comprise a greater amount of adenine and thymine/uracil nucleotides) in the gut microbiome while simultaneously maintaining or increasing the proportions of beneficial microflora.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*